Stock info Biogen | Filter  Basic-Info

Biogen

Biogen's headquarter is based in Weston. Biogen is mostly active in the biotech sector. Biogen is being led by CEO GEORGE A. SCANGOS. Paul J. Clancy runs the company as a CFO. The global biotech companies gained around 59 percent over the period 2006-2016. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year was a profitable year for Biogen investors

The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 4 percent. The period between August 2011 and August 2016 was a good period for the investors. The stock rose around 153 percent. Biogen's revenues between 2011 and 2015 were quite unstable and moved between 5,52 billion dollars and 10,76 billion dollars. Biogen's net incomes between 2011 and 2015 were very volatile and moved between 1,27 billion dollars and 3,61 billion dollars.

The American company didn't pay out any dividends (in the past 5 years).

At the end of 2015 around 7550 thousand people were employed at Biogen.

Biogen financed with a quite low debt position

Last year the balance sheet of the American company was worth 19,5 billion dollars. The total debt was around 10,13 billion dollars. This is 51,95 percent of the total balance sheet. At the end of 2015 the biotech company's stock was traded with a price/earnings-ratio 22. So the stock' value was 22 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 65,16 billion dollars. At the end of 2015 the American company had around 218,6 million stocks listed.

All the annual reports of Biogen are available here. More information about Biogen can be found it's website. .